Renova Therapeutics

Renova Therapeutics is a private, San Diego-based biotech founded in 2009, pioneering gene therapies for congestive heart failure and type 2 diabetes. The company's platform leverages AAV vectors to deliver therapeutic genes, with its lead candidate RT-100 (AC6 gene therapy) for heart failure and RT-200 (Urocortin-2 gene therapy) for type 2 diabetes advancing through clinical development. Renova has gained regulatory recognition in the UK via Innovation Passports for both programs and has secured NIH grant funding, positioning it to address massive, underserved chronic disease markets with a one-time treatment paradigm.

AAV vector-based gene therapy platform for durable, single-dose expression of therapeutic proteins (e.g., AC6, Urocortin-2) targeting underlying mechanisms of chronic diseases.

Renova competes in crowded therapeutic areas with large pharma and biotech companies. In heart failure, competitors range from standard-of-care drug developers to other gene/cell therapy pioneers. In diabetes, the landscape is dominated by GLP-1 agonists and SGLT2 inhibitors, with few gene therapy players, offering a differentiated but unproven mechanism.